Crawford Lake Capital Management LLC Sells 45,365 Shares of Amicus Therapeutics, Inc. (FOLD)

Crawford Lake Capital Management LLC cut its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 56.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 34,635 shares of the biopharmaceutical company’s stock after selling 45,365 shares during the quarter. Crawford Lake Capital Management LLC’s holdings in Amicus Therapeutics were worth $522,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. FMR LLC grew its stake in shares of Amicus Therapeutics by 3.4% during the 2nd quarter. FMR LLC now owns 21,437,508 shares of the biopharmaceutical company’s stock valued at $215,876,000 after acquiring an additional 705,153 shares during the period. Redmile Group LLC grew its stake in shares of Amicus Therapeutics by 5.9% during the 2nd quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after acquiring an additional 668,080 shares during the period. Jennison Associates LLC grew its stake in shares of Amicus Therapeutics by 9.4% during the 3rd quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock valued at $147,362,000 after acquiring an additional 838,267 shares during the period. Vanguard Group Inc. grew its stake in shares of Amicus Therapeutics by 5.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock valued at $91,821,000 after acquiring an additional 430,486 shares during the period. Finally, Palo Alto Investors LLC grew its stake in shares of Amicus Therapeutics by 0.7% during the 2nd quarter. Palo Alto Investors LLC now owns 7,940,788 shares of the biopharmaceutical company’s stock valued at $79,964,000 after acquiring an additional 57,800 shares during the period.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) opened at $12.51 on Wednesday. Amicus Therapeutics, Inc. has a 52 week low of $4.41 and a 52 week high of $16.60. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The business had revenue of $10.90 million during the quarter, compared to the consensus estimate of $9.02 million. During the same quarter in the previous year, the company earned ($0.33) earnings per share. The company’s revenue for the quarter was up 419.0% compared to the same quarter last year. sell-side analysts anticipate that Amicus Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

A number of research analysts recently issued reports on FOLD shares. J P Morgan Chase & Co reiterated an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. BidaskClub downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Chardan Capital restated a “buy” rating and issued a $16.50 price target (down from $17.50) on shares of Amicus Therapeutics in a research note on Wednesday, September 13th. Zacks Investment Research upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Tuesday, October 10th. Finally, Cowen restated an “outperform” rating and issued a $18.00 price target (up from $16.00) on shares of Amicus Therapeutics in a research note on Thursday, September 14th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $17.81.

In other Amicus Therapeutics news, insider Jay Barth sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $13.59, for a total value of $67,950.00. Following the completion of the transaction, the insider now directly owns 69,184 shares in the company, valued at approximately $940,210.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John F. Crowley sold 449,295 shares of the stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $14.33, for a total value of $6,438,397.35. Following the transaction, the chief executive officer now owns 380,723 shares of the company’s stock, valued at $5,455,760.59. The disclosure for this sale can be found here. Insiders sold a total of 633,224 shares of company stock valued at $9,091,953 over the last 90 days. 3.40% of the stock is currently owned by corporate insiders.

WARNING: “Crawford Lake Capital Management LLC Sells 45,365 Shares of Amicus Therapeutics, Inc. (FOLD)” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.com-unik.info/2017/12/06/crawford-lake-capital-management-llc-sells-45365-shares-of-amicus-therapeutics-inc-fold.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

What are top analysts saying about Amicus Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amicus Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit